Skip to main content
Equibles
PROK logo

PROK · Prokidney Corp. · Metrics

Track PROK — free

Use PROK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PROK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.41 -0.02 (-1.40%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on our current operating plan, we do not believe our existing cash and cash equivalents and marketable securities as of June 30, 2026, will be sufficient to fund our obligations for the 12 months following the issuance of the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q on August 10, 2026. Accordingly, substantial doubt exists about our ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q are issued.”
View the 10-Q filed Aug 10, 2026
Market Cap
$426.27M
Shares
302.32M
Volume · Oct 23 535.23K Avg daily vol (3M) 1.3M

PROK metrics

65 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.41
Market cap
$426.27M

Price action

20 metrics
Price change (1W)
+6.0%
Price change (30D)
-11.9%
Price change (3M)
-6.0%
Price change (6M)
-27.3%
Price change (YTD)
-37.1%
Price change (1Y)
-55.8%
Trailing year
Price change (5Y)
-85.7%
52-week high
$3.22
52-week low
$1.33
Change from 52-week high
-56.2%
Change from 52-week low
+6.0%
Annualized volatility
71.5%
Annualized volatility (3M)
71.3%
Beta
1.8
RSI (14D)
38.9
Price vs SMA 50
-15.2%
Price vs SMA 200
-23.4%
Avg volume (3M)
1.30M
Relative volume
0.4
Average dollar volume
$2.17M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
302.32M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
521.1×
reciprocal yield 0.2%
P / book
—
FCF yield
-37.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-19.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2024-05-10

Profitability

9 metrics
Gross margin
—
Operating margin
-21,664.5%
Trailing 12 months
Net margin
-10,288.4%
Gross profit (TTM)
—
Operating profit (TTM)
−$177.22M
Net income (TTM)
−$84.16M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-19,527.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
-32.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$818,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-33.8%
Debt / equity
—
Current ratio
8.4
EBITDA (TTM)
−$170.37M
Free cash flow (TTM)
−$159.73M
Quick ratio
8.4
Interest coverage
-9,327.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$74.87M
Latest balance sheet
Cash & equivalents
$74.87M
Total assets
$249.02M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$141.17M
Capital expenditures (TTM)
$18.57M
R&D (TTM)
$130.91M
SG&A (TTM)
—
Stock compensation (TTM)
$22.92M
R&D / revenue
16,004.3%
Stock compensation / revenue
2,801.7%

Ownership (13F)

9 metrics
13F filers
71
13F filer change QoQ
0
Institutional ownership
15.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-7.2%
Holder tenure
3.8
Price vs estimated holder cost
-17.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
2.0%

Short interest

3 metrics
Short interest
7.9%
Latest settlement · 11.0 days to cover
Days to cover
11.0d
Short-squeeze score
72 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.07M
Insider-sentiment score
29 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1850270 CUSIP 74291D104 13F (30d) 12 filings 12 filers Visit website Investor relations